Amneal Pharmaceuticals, Inc. Quarterly Operating Income (Loss) in USD from Q2 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Amneal Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2017 to Q3 2024.
  • Amneal Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was $88.8M, a 17.4% increase year-over-year.
  • Amneal Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was $188M, a 17% decline year-over-year.
  • Amneal Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was $204M.
  • Amneal Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$94.9M, a 162% decline from 2021.
  • Amneal Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was $153M, a 67.5% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $188M $88.8M +$13.2M +17.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $175M $95.5M +$15.4M +19.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 $159M -$10.7M -$45.2M -131% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $204M $14.2M -$21.8M -60.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 $226M $75.6M +$31.3M +70.6% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $195M $80.1M +$279M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 -$83.8M $34.4M +$11.1M +47.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$94.9M $36M +$24.9M +222% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 -$120M $44.4M +$15.8M +55.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$136M -$199M -$266M -396% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $130M $23.3M -$22.6M -49.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $153M $11.2M -$9M -44.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-14
Q3 2021 $162M $28.5M +$26.1M +1071% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $136M $67.1M +$56.4M +524% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $79.3M $45.9M -$11.9M -20.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 $91.2M $20.2M +$43.3M Oct 1, 2020 Dec 31, 2020 10-K 2023-03-03
Q3 2020 $47.8M $2.44M +$115M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$66.9M $10.8M +$29.7M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$96.5M $57.8M +$152M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 -$249M -$23.1M -$46.4M -199% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 -$202M -$112M -$187M -251% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 -$15.4M -$18.9M +$162M +89.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$178M -$94.4M -$158M -248% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 -$19.7M $23.3M Oct 1, 2018 Dec 31, 2018 10-K 2021-03-01
Q3 2018 $74.6M -$4.2M -5.33% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$181M -$226M -506% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-05
Q1 2018 $63.6M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q3 2017 $78.8M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $44.6M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.